CD274 and non-small cell lung carcinoma: However, in NSCLC patients, humanized anti-PD-L1 antibody treatment led to a relatively lower objective response rate, higher 3- and 4-grade adverse effect rates, and higher number of drug-related deaths compared with chemotherapy or tyrosine kinase inhibitor (TKI) therapy [32].